Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Therapeutic Discovery

Combination of Rad001 (Everolimus) and Propachlor Synergistically Induces Apoptosis through Enhanced Autophagy in Prostate Cancer Cells

Sheng Tai, Yin Sun, Nan Liu, Boxiao Ding, Elaine Hsia, Sunita Bhuta, Ryan K. Thor, Robert Damoiseaux, Chaozhao Liang and Jiaoti Huang
Sheng Tai
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yin Sun
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nan Liu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Boxiao Ding
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elaine Hsia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sunita Bhuta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ryan K. Thor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Damoiseaux
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chaozhao Liang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jiaoti Huang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-11-0954 Published June 2012
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Identification of propachlor as a collaborating compound with Rad001. A, five thousand compounds were added alone or together with 20 nmol/L Rad001 in C4-2 cells, the survival ratio gauged by ATP measurement between cells that are treated with single compound or combination with Rad001 is plotted. B, the chemical structures of Rad001 and propachlor. C, propachlor can collaborate with Rad001 to inhibit PC3 and C4-2 cells. Single compounds or combination with Rad001 were used to treat PC3 or C4-2 cells for 72 hours followed by CellTiter-Glo measurement to measure cell number. The 2-way t test showed P < 0.05 between the 2 groups.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    The combination of Rad001 and propachlor induces a synergistic reduction of cell number in prostate cancer cells. A, decreasing doses of Rad001 alone, propachlor alone, and their combination were used, and cell numbers measured as in Fig. 1 (x-axis, Rad001 μmol/L; y-axis, propachlor μmol/L; z-axis, 1 − (treatment luminescence unit/control luminescence). B, normalized isobologram analysis showed synergistic interactions in PC3 and C4-2 cells. The analysis was done with CalcuSyn software, which conducts the drug dose–effect calculation with the median effect method described by Chou (7). A large number of combination groups were below the line, indicating synergism. C, growth curves by measuring ATP level shows more reduction of cell number when cells were treated with the drug combination.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Combination of Rad001 and propachlor synergistically induces cell death in prostate cancer cells. PC3 cells were treated with DMSO (control), Rad001 (0.70 μmol/L), propachlor (6.15 μmol/L), or their combination, and C4-2 cells were treated with DMSO (control), Rad001 (0.56 μmol/L), propachlor (7.05 μmol/L), or their combination. A, trypan blue (TB) assay. Combination treatment resulted in lower cell viability than either compound alone (2-way t test: P < 0.005). B, increased levels of cleaved PARP1 and caspase-3 and decreased Bcl-2 in PC3 and C4-2 cells treated for 15 hours with the combination of Rad001 and propachlor. Lysates from cells were separated by SDS-PAGE followed by immunoblotting with respective antibodies. C, higher activities of caspase-3/7 in PC3 and C4-2 cells treated for 15 hours with the drug combination. D, flow cytometric analysis of apoptosis with Annexin-V and 7-AAD staining. There was a significant increase in the percentage of apoptotic cell after combination treatment versus single compound (P < 0.05).

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Rad001 and propachlor combination synergistically induces autophagy in PC3 and C4-2 cells. Autophagy was analyzed after 1 day of treatment. PC3 cells were treated with DMSO (control), Rad001 (0.70 μmol/L), propachlor (6.15 μmol/L), or their combination, and C4-2 cells were treated with DMSO (control), Rad001 (0.56 μmol/L), propachlor (7.05 μmol/L), or their combination. A, upregulation of LC3-2 in PC3 and C4-2 cells treated with combination of the 2 compounds. Immunoblotting was conducted as in Fig. 3. B, increased autophagosomes (arrows) were observed by electron microscopy in cells treated with Rad001/propachlor compared with each compound alone. Quantified data from 30 cells are shown in the bottom. C, autophagosome analysis through GFP-LC3 expression. C4-2 and PC3 cells expressing GFP-LC3 were treated with DMSO, Rad001, propachlor, or their combination for 24 hours. The cells were fixed with paraformaldehyde and visualized with epifluorescence. Yellow arrows indicate the punctate pattern of GFP-LC3, representative of autophagosome, and nuclei were visualized through DAPI staining. The number of GFP-LC3 punctuate dots/cells was quantitated in 50 GFP+ cells from each group (bottom).

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Regulation of autophagy proteins in response to combination treatment of Rad001 and propachlor. A, Atg5–Atg12 conjugates and Beclin1 were induced in response to combination treatment for 24 hours. Immunoblotting was conducted as in Fig. 3. B, Beclin 1 mRNA was more significantly upregulated by the combination treatment as shown by qRT-PCR analyses (left). Right, shows that Beclin1 mRNA stability does not increase in response to the combination treatment. C, Beclin1 is critical for the autophagic death induced by the combination treatment. PC3 and C4-2 cells were transfected with control siRNA or siRNA for Beclin1 (right). Cells were treated with combination of Rad001 and propachlor 24 hours after transfection. The cell number was determined with ATP measurement 24 hours after the combination treatment.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    Combination of Rad001 and propachlor significantly inhibits the PC3 xenograft tumors in mice. A, antitumor activity on PC3 xenografts by various compounds. Mice were administered daily i.p. with Rad001 (1 mg/kg), propachlor (5 mg/kg), or both (6 mice/group). The tumor sizes (left) and body weights (right) were measured every 4 days. Tumors treated with 2 drugs were much smaller than single compound treatment or control. B, electron microscopic analysis of the tumors collected from various treatment groups. Arrows indicate autophagosomes. C, quantitation of the number of autophagosomes in 30 cells from the xenograft tumors. D, immunoblot analysis for LC3 and Beclin1 from the xenograft tumors.

Additional Files

  • Figures
  • Supplementary Data

    Files in this Data Supplement:

    • Supplementary Figure Legend - PDF file, 70KB.
    • Supplementary Figure 1 - PDF file, 66KB, Mixture-Algebraic estimate analysis of the combination index (CI) values.
    • Supplementary Figure 2 - PDF file, 258KB, Cell-cycle distribution histograms.
    • Supplementary Table 1 - PDF File, 1123KB, The combination index (CI) values of each mixture treatment calculated with CalcuSyn software for PC3 (A) and C4-2 (B) cells.
PreviousNext
Back to top
Molecular Cancer Therapeutics: 11 (6)
June 2012
Volume 11, Issue 6
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Combination of Rad001 (Everolimus) and Propachlor Synergistically Induces Apoptosis through Enhanced Autophagy in Prostate Cancer Cells
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Combination of Rad001 (Everolimus) and Propachlor Synergistically Induces Apoptosis through Enhanced Autophagy in Prostate Cancer Cells
Sheng Tai, Yin Sun, Nan Liu, Boxiao Ding, Elaine Hsia, Sunita Bhuta, Ryan K. Thor, Robert Damoiseaux, Chaozhao Liang and Jiaoti Huang
Mol Cancer Ther June 1 2012 (11) (6) 1320-1331; DOI: 10.1158/1535-7163.MCT-11-0954

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Combination of Rad001 (Everolimus) and Propachlor Synergistically Induces Apoptosis through Enhanced Autophagy in Prostate Cancer Cells
Sheng Tai, Yin Sun, Nan Liu, Boxiao Ding, Elaine Hsia, Sunita Bhuta, Ryan K. Thor, Robert Damoiseaux, Chaozhao Liang and Jiaoti Huang
Mol Cancer Ther June 1 2012 (11) (6) 1320-1331; DOI: 10.1158/1535-7163.MCT-11-0954
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Grant Support
    • Acknowledgments
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Sorafenib Targets VCP in Hepatocellular Cancer Cells
  • RSK2 as Therapeutic Target for Myeloma
  • Dll4-Fc Suppresses Liver Metastasis of SCLC Cells
Show more Therapeutic Discovery
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement